Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape
The case, originally filed in 2021 by Harbour Antibodies, asserted that Amgen and Teneobio (an Amgen subsidiary) infringed patents protecting Harbour's groundbreaking antibody discovery platform Delaware jury finds infringement willful and patent...
Xiao-I Corporation Provides Further Update on Shanghai Xiao-I's Patent Infringement Lawsuit Against Apple
SHANGHAI, March 31, 2026 /PRNewswire/ -- Xiao-I Corporation (NASDAQ: AIXI), a leading developer of AI solutions, today provides an additional material update on its variable interest entity (VIE)'s ongoing patent infringement lawsuit against Apple...
China National Intellectual Property Administration Affirms Validity of Harbour BioMed's Patent; Infringement Lawsuit Moves Forward
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SHANGHAI, June 16, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics focusing on immunology...